Abbott secures EUA for SARS-CoV-2 antibody blood test

By staff writers

May 11, 2020 -- Abbott has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a SARS-CoV-2 immunoglobulin G (IgG) lab-based serology blood test for use with its Alinity i system.

The test is Abbott's fourth COVID-19 assay to receive an EUA. It has demonstrated 99.6% specificity and 100% sensitivity in patients tested 14 days after symptoms manifest, according to the firm. Abbott plans to ship 30 million of the tests this month for use with its Architect and Alinity i platforms; it will have capacity for 60 million in June, it said.

The company expects to receive the CE Mark for the test this week, Abbott said.

Abbott bolsters SARS-CoV-2 antibody test with new study
Abbott has published data showing that its SARS-CoV-2 antibody blood test has 100% sensitivity and 99.9% specificity for detecting immunoglobulin G in...
Abbott unveils lab-based COVID-19 antibody blood test
Abbott has debuted a lab-based serology blood test for the detection of immunoglobulin G, the antibody that identifies if a person has had COVID-19. The...
Abbott's 'lightning fast' coronavirus test takes center stage in U.S. pandemic strategy
Abbott's newly approved ultrarapid molecular point-of-care test for the novel coronavirus featured prominently in the White House's coronavirus task force...
Abbott ships 150K coronavirus tests to U.S. hospitals
Abbott is shipping 150,000 tests for the novel coronavirus to hospitals and academic medical centers in the U.S., following the receipt of an emergency...
Abbott, Intoximeters partner on roadside drug test
Breath alcohol testing products company Intoximeters is set to market Abbott's SoToxa oral fluid point-of-care test, which screens for the recent use...

Copyright © 2020

Last Updated ls 5/11/2020 11:41:25 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current